Status:
UNKNOWN
Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells
Lead Sponsor:
Stem Cells Arabia
Conditions:
Use of Stem Cells for COVID-19 Treatment
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing...
Detailed Description
COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnos...
Eligibility Criteria
Inclusion
- COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.
Exclusion
- Participants in other clinical trials
- patients with malignant tumors
- pregnant and lactating women
- co-infection with other infectious viruses or bacteria
- History of several allergies
- Patients with history of pulmonary embolism
- any liver or kidney diseases
- HIV positive patients
- Considered by researchers to be not suitable to participate in this clinical trial
- Chronic heart failure with ejection fraction less than 30%.
Key Trial Info
Start Date :
March 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2020
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04313322
Start Date
March 16 2020
End Date
September 30 2020
Last Update
March 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stem Cells Arabia
Amman, Jordan, 11953